1May2012

1. Protocol Number: FWH20090166A

2. Type of Research:

1) Animal Research

3. Title:

"A Comparison of Proximal Tibia, Proximal Humerus and Distal Femur Infusion Rates of Blood Under High Pressure Using the EZ IO Intraosseous Device on the Adult Swine (Sus scrofa) hypovolemic Model."

4. Principal Investigator (PI):

Name	Rank	Date of	Branch	Staff	Department /	Email	Phone	Pager
		IACUC	of	Resident	Office	(if other than		
		Training	Service/	Fellow	Symbol	WHASC		
			Corps	Civilian		Outlook)		
Julio Lairet	LtCol	26 Oct	MC	Staff	59th		WP: 916-	Cell: 210-
		2009			EMDS/SG		7836	867-0848
					O3D		FAX:	
							292-7649	

5. Purpose:

The purpose of this study is to evaluate the use of blood product administration through an IO under pressures >300mmHg. A secondary objective of this study will be the establishment of which IO site between the proximal tibia, proximal humerus and the distal femur can reach the higher flow rates. Data from Lairet et al. have postulated that the proximal humerus appears to deliver higher flow rates than the other two sites. This fact also needs to be validated.

6. Results:

The mean maximum infusion pressure was 538 mmHg (SD 80 mmHg) for the humerus, 630 mmHg (SD 80 mmHg) for the femur, and 650 mmHg (SD 76 mmHg) for the tibia. The mean infusion rate for the tibia was 78 mL/min (SD 38.5 mL/min), 49 mL/min (SD 45.1 mL/min) for the femur and 103 mL/min (SD 34.1 mL/min) for the humerus. Infusion rate comparison of all the sites using ANOVA revealed a p < 0.005. Comparing the infusion rates of the humerus (103 mL/min) to the femur (49 mL/min) revealed a p < 0.01. Comparisons between the tibia with the humerus and femur did not reveal statistical significance. All the animals in the tibia arm survived to the end of the experiment; in the femur and humerus arms the survival rate was 12/14 (86%) and 11/14 (79%) respectively. In the tibia and humerus arms the serum lactate increased during the hypovolemic period and decreased after infusion of blood. In the femur arm the serum lactate increased until the experiment ended. Histopathologic examination revealed that fat emboli were present in 14/14 (100%) of the tibia arm, 10/11 (91%) of the humerus arm (samples from 3 swine were inadequate), and 8/14 (57%) of the femur group.

For the proof of concept portion of the protocol amendment #2

The baseline MAP were similar (Table). After removal of the blood the mean MAP at hypotension were also similar (Table) Comparison of the MAP for the post hydroxocobalamin administration groups using ANOVA revealed a p < 0.001. Post HOC analysis using the Tukey honestly significant difference (HSD) between groups revealed statistical difference between group 1 to groups 2 and 3 (p<0.001) but not when comparing groups 2 and 3 (p<0.844). The baseline SVR prior to removing the blood for group 1 was 841.5 (SD 36), group 2 - 975 (SD 24) and group 3 - 642.5 (SD 3.5). At hypotension the mean SVR was similar in all 3 groups. The mean SVR for each group in the 90 min post administration of hydroxocobalamin was 1025 (SD 194) for group 1, 1099 (SD 135) for group 2 and 726 (SD 130) for group 3. Comparison of the post hydroxocobalamin administration groups using ANOVA revealed a p < 0.001. The baseline Heart Rate (HR) prior to removing the blood for group 1 was 96.5 (SD 19), 75 (SD 10) for group

For Protocol Office Use Only:							
Received on:	•	_ Report Due	e Date	_ Sched	uled for IACUC:		
Copy to Budget? Yes No	BIRDS	Agenda	Who Signed? PI	Co-PI	Auth AI		
For Review Purposes Only							
Eligible for Expedited Approv	Signature_		D	ate:			

2 and 76 (SD 10) for group 3. After removal of the blood the mean HR for group 1 was 96 (SD 25), 95.5 (SD 5) for group 2 and 78.5 (SD 0.7) for group 3. The mean HR for each group in the 90 min post administration of hydroxocobalamin was 106 (SD 7) for group 1, 90 (SD 5) for group 2 and 83 (SD 13) for group 3. Comparison of the post hydroxocobalamin administration groups using ANOVA revealed a p < 0.001.

	Mean Baseline MAP	Mean MAP after at 50% MAP	Mean MAP after hydroxocobalamin administration	% return back to baseline at 90 minutes
Group 1	83 (SD 1.4)	41 (SD 3.1)	87 (SD 23)	105 %
Group 2	67.5 (SD 3.5)	34.5 (SD 2.1)	61 (SD 3.5)	90 %
Group 3	77 (SD 15.6)	38 (SD 5.7)	60 (SD 4.5)	78 %

Conclusion: Intraosseous hydroxocobalamin significantly increased mean arterial blood pressure and systemic vascular resistance in our pilot, dose-finding hemorrhagic shock swine model. The blood pressure response paralleled increasing drug dose. Hydroxocobalamin may prove to be a pharmacologic adjunct for hemorrhagic shock.

7. How may your findings benefit the Air Force?

The results of this study suggest that the humerus may be a better site for administration through an intraosseous device. The fact that fat emboli were seen in the lungs needs to be further studied as this finding if confirmed would suggest that intraosseous devices might only be used in emergency situations.

The information learned from the proof of concept has allowed Lt Col Bebarta to apply and receive a research grant to further study the concept of administering hydroxocobalamin for hemorrhagic shock.

8. Number of Animals

Projected Enrollment of Animals at the Beginning of Study: 46

Amendment 2: Added 6 animals as a proof of concept model to use hydroxocobalamin for hemorrhagic shock.

<u>Amendment 3:</u> Requested an **additional 3 animals** for repeat of the first 3 animals of the femur arm. It was discovered that the length of the IO needle was not adequate to get the needle into the proper location of the bone for re-infusion of the blood.

Actual Number of Animals Enrolled: 55

9. Status of Animals Entered Into the Protocol:

All animals were in good general health and were euthanized per protocol.

10. Status of Funds:

All funds were executed.

11. Reason for Closure:

Objectives of the study were met

12. Specific Problems:

During the femur arm we discovered that the needle length was not long enough to reach the marrow of the bone. This was corrected by performing dissection to the bone prior to placement. No issues were encountered after this correction of technique.

13. Publications and Pr	esentations	:			
None					
Presentations:					
None					
Publications:					
None					
14. Exceptional Achiev	ements:				
None					
Julio Lairet, Maj, USAF, M Director Enroute Care Re	AC search Center	er			
For Protocol Office Us				a	
Received on:	Initials		e Date		
Copy to Budget? Yes No For Review Purposes	BIRDS Only	Agenda	Who Signed? PI	Co-PI Auth AI	

Eligible for Expedited Approval? Yes No Signature_______Date:_____

REPORT DOCUMENTATION PAGE						2		
watnermy and manu	annina tino uata noodo	a. una completina un	0 10 110 1110 UNICOLIO UL IIII	ormation, pond con	miletita regui	IO 101 164/644410 HIGHUGHUIS, SOULUMB CANTING USES SOULCES. UMB THIS DATEST CANTING OF BITY OUTST LABOUR OF THIS CONSCIONT BYTHOS. PROCEEDING OF THIS MICH.		
300000 to dily bondi	CONTRACTOR LO CONTRA	WOV. DUILG 1207. AL		vonuenta anoune de	-	PULTERINITATION OF THE PULL OF PULL OF PARTY OF		
			IE ABUVE ADDKESS.					
1. KEPUKI DA	-07-2012	. Z. REPU	Final			August 2009 - May 2012		
4. IIILE AND	PORILIFE				ba. cur	VIRACI NUMBER		
A comparison of proximal tibia, proximal humerus and distal femur infusion								
rates of blood under high pressure using the EZ IO intraosseous device in the					DD. GRANI NUMBER			
adult swine (Sus scrofa) hypovolemic model.					FWH20090166A			
					SC. PRUGRAM ELEMENT NUMBER			
b. AUTHURIS					ba. PHU	JECT NOWBER		
Lairet, Julio						FWH20090166A		
Bebarta, Vikhy	yat				be. IAS	ok MOINIRER		
				1	bī. WUI	KK UNIT NUWBEK		
/. PEKFUKIVIIN	IG UKGANIZATI	UN NAIVIE(5) AN	ND ADDRESSIESI			8. PERFURINING UNGANIZATION		
59th EMS						KEPUKI NUWBEK		
Wilford Hall A						FWH20090166A		
2200 Bergquis		550						
Lackland AFB, TX 78236 9. SPUNSUKING/MUNITUKING AGENCY NAME(S) AND ADDRESSIES) 10. SPUNSUK/MUNITUK S ACKUNYMIS)								
Office of the Air Force Surgeon General								
Directorate for Modernization, SGRS								
5201 Leesburg Pike, Suite 1206						11. SPUNSUK/MUNITUK S KEPUKT		
Falls Church, VA 22401						NOMBER(5)		
12. DISTRIBUTION/AVAILABILITY STATEMENT								
Distribution A								
13. SUPPLEMENTARY NUTES								
14. AB51KAU1								
		es of blood adn	ninistered through intra	aosseous (IO)	needle ir	n proximal tibia and humerus, and distal		
femur under hi	gh pressure(>3	00mmHg) in a	dult hypovolemic (sus	scrofa). MET	HOD:3 g	groups of animals; 14 per group were		
intubated and v	ventilated. Cen	tral vein and ar	terial lines were placed	d, blood was r	emoved i	until MAP is 50% of baseline. An EZIO		
						ns of fat emboli (FE). FINDINGS:Mean		
infusion rate fo	or tibia was 78r	nL/min(SD 38.	5mL/min), 49mL/min	(SD 45.1mL/r	nin) for f	emur and 103mL/min(SD 34.1mL/min) for		
						ring the infusion rates of humerus(103		
mL/min) to femur(49mL/min) revealed a p<0.01. Comparisons of tibia with humerus and femur revealed no statistical significance. Histopath exam revealed FE were present in 100% of tibia arm, 91% of humerus arm, and 57% of femur arm. CONCLUSION:rate of								
IO infusion of blood through the humerus was greater than femur and tibia. FE detected in lungs of most animals.								
15. SUBJECT TERMS								
Blood infusion scrofa, animal		infusion, Intra	osseous Infusion, IO, I	EZ IO, Intraos	seous, In	traosseous femur, resuscitation, swine, sus		
ID. SECURITY	CLASSIFICATIO	N UF:	17. LIMITATION OF	IS. NUNBER	19a. NA	VIE UF KESPUNSIBLE PEKSUN		
a. REPURT D. ABSTRACT C. THIS PAGE ABSTRACT UF			Vikhyat Bebarta, MD					
U	U	U	SAR	PAGES		EPHUNE NUIVIBER		
J	J	J				210-292-3908		